FDG-PET/CT in Assessing the Tumor and Planning Neck Surgery in Patients With Newly Diagnosed H&N Cancer

Head and Neck Cancer Clinical Trial

— ACRIN6685  

Official title:

A Multicenter Trial of FDG-PET/CT Staging of Head and Neck Cancer and Its Impact on the N0 Neck Surgical Treatment in Head and Neck Cancer Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00983697
• Other study ID #: CDR0000654703
• Secondary ID: ACRIN-6685U01CA0
• Status: Active, not recruiting
• Phase: N/A
• Start date: April 1, 2010
• Est. completion date: December 2021

Study information

• Verified date: October 2020
• Source: American College of Radiology Imaging Network
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18-PET/CT scan, may help doctors find head and neck cancer and find out how far the disease has spread. It may also help doctors plan the best treatment.

PURPOSE: This phase II trial is studying fludeoxyglucose F 18-PET/CT imaging to see how well it works in assessing the tumor and planning neck surgery in patients with newly diagnosed head and neck cancer.

Description:

OBJECTIVES:

Primary

• Determine the negative predictive value of PET/CT imaging based upon pathologic sampling of the neck lymph nodes in patients with head and neck cancer planning to undergo N0 neck surgery.

• Determine the potential of PET/CT imaging to change treatment.

Secondary

• Estimate the sensitivity and diagnostic yield of PET/CT imaging for detecting occult metastasis in the clinical N0 neck (both by neck and lymph node regions) or other local sites.

• Determine the effect of other factors (e.g., tumor size, location, secondary primary tumors, or intensity of FDG uptake) that can lead to identification of subsets of patients that could potentially forego neck dissection or that can provide preliminary data for subsequent studies.

• Compare the cost-effectiveness of using PET/CT imaging for staging head and neck cancer vs current good clinical practices.

• Evaluate the incidence of occult distant body metastasis discovered by whole-body PET/CT imaging.

• Correlate PET/CT imaging findings with CT/MRI findings and biomarker results.

• Evaluate the quality of life of these patients, particularly of those patients whose management could have been altered by imaging results.

• Evaluate PET/CT imaging and biomarker data for complementary contributions to metastatic disease prediction.

• Compare baseline PET/CT imaging and biomarker data with 2-year follow up as an adjunct assessment of their prediction of recurrence, disease-free survival, and overall survival.

• Determine the proportion of neck dissections that are extended (i.e., additional levels that clinicians intend to dissect beyond the initial surgery plan) based on local-reader PET/CT imaging findings shared with the surgeon before dissection.

• Estimate the optimum cutoff value of standardized uptake values for diagnostic accuracy of PET/CT imaging.

• Evaluate the impact of PET/CT imaging on the N0 neck across different tumor subsites (defined by anatomic location).

OUTLINE: This is a multicenter study.

Patients undergo fludeoxyglucose F 18-PET/CT imaging. Approximately 14 days later, patients undergo unilateral or bilateral neck dissection.

Patients complete quality-of-life questionnaires at baseline and at 1, 12, and 24 months after surgery.

Patients undergo blood and tissue sample collection periodically for biomarker analysis.

Patients are followed up periodically for up to 2 years after surgery.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 292
• Est. completion date: December 2021
• Est. primary completion date: January 15, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed newly diagnosed squamous cell carcinoma (SCC) of the head and neck , including any of the following sites:

• Oral cavity

• Oropharynx, including base of tongue and tonsils

• Larynx

• Supraglottis

• Stage T2-T4, N0-N3 disease

• Unilateral or bilateral neck dissection planned

• No N2c disease (if bilateral disease is present)

• Has = 1 clinically N0 neck side as defined by clinical exam (physical exam with CT scan and/or MRI)

• A N0 neck must be planned to be dissected for the patient to be eligible

• . The N0 neck can be either ipsilateral to the head and neck tumor or the contralateral N0 neck if a bilateral neck dissection is planned

• CT scan and/or MRI taken within the past 4 weeks to confirm SCC of the head and neck

• Simultaneous diagnostic CT with PET scan allowed; however, PET cannot be used as part of the criteria to define the N0 neck disease

• For CT scan and/or MR images from other institutions, ACRIN recommends a re-read by a local neuro-radiologist to ensure compliance

• No sinonasal cancer, salivary gland cancer, thyroid cancer, nasopharyngeal cancer, or advanced skin cancer

PATIENT CHARACTERISTICS:

• Not pregnant or nursing

• Negative pregnancy test

• Weight = 350 lbs

• No poorly controlled diabetes (defined as fasting glucose level > 200 mg/dL) despite attempts to improve glucose control by fasting duration and adjustment of medications (optimally, patients will have glucose < 150 mg/dL)

• No underlying medical condition that would preclude surgery (neck dissection)

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

Related Conditions & MeSH terms

• Head and Neck Cancer
• Head and Neck Neoplasms

Intervention

Procedure:
• therapeutic conventional surgery

Radiation:
• fludeoxyglucose F 18

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing
United States	Arkansas Cancer Research Center at University of Arkansas for Medical Sciences	Little Rock	Arkansas
United States	USC/Norris Comprehensive Cancer Center and Hospital	Los Angeles	California
United States	Jewish Hospital Heart and Lung Institute	Louisville	Kentucky
United States	Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania
United States	Fox Chase Cancer Center - Philadelphia	Philadelphia	Pennsylvania
United States	Kimmel Cancer Center at Thomas Jefferson University - Philadelphia	Philadelphia	Pennsylvania
United States	Mayo Clinic Cancer Center	Rochester	Minnesota
United States	Morton Plant Mease Cancer Care at Mease Countryside Hospital	Safety Harbor	Florida
United States	Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis	Saint Louis	Missouri
United States	H. Lee Moffitt Cancer Center and Research Institute at University of South Florida	Tampa	Florida
United States	Wake Forest University Comprehensive Cancer Center	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
American College of Radiology Imaging Network	National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  China, 

References & Publications (1)

Lowe VJ, Duan F, Subramaniam RM, Sicks JD, Romanoff J, Bartel T, Yu JQM, Nussenbaum B, Richmon J, Arnold CD, Cognetti D, Stack BC Jr. Multicenter Trial of [(18)F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Negative predictive value of PET/CT imaging for staging the N0 neck based upon pathologic sampling of the neck lymph nodes	True negative cases will be determined by histopathology reports. The test will be defined as positive when SUVmax value of = 2.0; and negative otherwise.	Within Two Weeks Before Surgery and after sampling of neck lymph nodes
Secondary	Sensitivity and diagnostic yield of PET/CT imaging for detecting occult metastasis in the clinically N0 neck (both by neck and lymph node regions) or other local sites	True positive cases will be determined by histopathology reports. The test will be defined as positive when SUVmax value of = 2.0; and negative otherwise. The diagnostic yield is defined as the ratio of cancers to total screened	Within Two Weeks Before Surgery and after sampling of neck lymph nodes
Secondary	Determine which factors (e.g., tumor size, secondary primary tumors, location, or intensity of FDG uptake) may identify patients who can forego neck dissection	True positive cases will be determined by histopathology reports. The test will be defined as positive when SUVmax value of = 2.0; and negative otherwise. The diagnostic yield is defined as the ratio of cancers to total screened	Within Two Weeks Before Surgery and after sampling of neck lymph nodes
Secondary	Cost-effectiveness and cost-benefit of using PET/CT imaging for staging of head and neck cancer vs current good clinical practices	The outcome measure will use the total cost of care for each participant to compute the incremental cost-effectiveness ratio (ICER)	2 years post-surgery
Secondary	Incidence of occult distant body metastasis discovered by whole body PET/CT imaging	this outcome will count the distant body metastasis not previously seen and report the results as a percentage.	Within Two Weeks Before Surgery
Secondary	Correlation of PET/CT imaging findings with CT/MRI findings and biomarker results	the outcome measure will consist of paired proportions of dichotomized PET/CT and CT/MRI test results; and biomarker test results	Within Two Weeks Before Surgery
Secondary	Quality of life (QOL), particularly in patients whose management could have been altered by imaging results	QOL will be assessed using SF-36, Non-Utility HUI, and UW-QoL scores	2 years post-surgery
Secondary	Evaluation of the PET/CT imaging and biomarker data for complementary contributions to metastatic disease prediction	the metastatic disease status is the response variable and PET/CT test results and biomarker data are predictors.	Within Two Weeks Before Surgery
Secondary	Comparison of baseline PET/CT imaging and biomarker data with 2-year follow up as an adjunct assessment of their prediction of recurrence	model the associations of PET/CT test results and biomarker data (predictors) to recurrence	2 years post-surgery
Secondary	Comparison of baseline PET/CT imaging and biomarker data with 2-year follow up as an adjunct assessment of their prediction of disease-free survival	model the associations of PET/CT test results and biomarker data (predictors) to disease-free survival	2 years post-surgery
Secondary	Comparison of baseline PET/CT imaging and biomarker data with 2-year follow up as an adjunct assessment of their prediction of overall survival	model the associations of PET/CT test results and biomarker data (predictors) to overall survival (censored responses)	2 years post-surgery
Secondary	Proportion of neck dissections that are extended based on local-reader PET/CT imaging findings shared with the surgeon before dissection	Outcome is defined as the number patients who surgeons intend to dissect levels beyond the initial surgery plan	Within Two Weeks Before Surgery
Secondary	Optimum cutoff value of standardized uptake values for diagnostic accuracy of PET/CT imaging	ROC analysis will be used to maximize the youden index and estimate the optimum cutoff value of SUV for diagnostic accuracy of PET/CT on N0 neck	Within Two Weeks Before Surgery
Secondary	Impact of PET/CT imaging on the N0 neck across different tumor subsites (defined by anatomic location)	Diagnostic Accuracy measures will be calculated using ROC analysis, subset by anatomic location	Within Two Weeks Before Surgery

External Links

•   National Cancer Institute's clinical trials database